Changes

15. Shechter I, et al, (2003). IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J Lipid Res 44:2169–2180, PMID 12923220.  

15. Shechter I, et al, (2003). IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J Lipid Res 44:2169–2180, PMID 12923220.  

16. Joseph, J. W. et al. The Mitochondrial Citrate/Isocitrate Carrier Plays a Regulatory Role in Glucose-stimulated Insulin Secretion. J. Biol. Chem. 281, 35624–35632 (2006). PMID: 17001083

16. Joseph JW, et al., (2006). The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion. J Biol Chem 281:35624–35632, PMID 17001083.

17. Koh, H.-J. et al. Cytosolic NADP + -dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism. J. Biol. Chem. 279, 39968–39974 (2004). PMID: 15254034  

17. Koh H-J, et al., (204). Cytosolic NADP + -dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem 279:39968–39974, PMID 15254034.

18. Ronnebaum, S. M. et al. A Pyruvate Cycling Pathway Involving Cytosolic NADP-dependent Isocitrate Dehydrogenase Regulates Glucose-stimulated Insulin Secretion. J. Biol. Chem. 281, 30593–30602 (2006). PMID: 16912049  

18. Ronnebaum SM, et al., (2006). A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem 281:30593–30602, PMID 16912049.

19. Reitman, Z. J. & Yan, H. Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. JNCI J. Natl. Cancer Inst. 102, 932–941 (2010). PMID: 20513808  

19. Reitman ZJ and Yan H, (2010). Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932–941, PMID 20513808.

20. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009). PMID: 23532369

20. Yan H, et al., (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773, PMID 23532369.

21. Sanson, M. et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. J. Clin. Oncol. 27, 4150–4154 (2009). PMID: 19636000  

21. Sanson M, et al., (2009). Isocitrate dehydrogenase 1 Codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154, PMID 19636000.

22. Nobusawa, S., Watanabe, T., Kleihues, P. & Ohgaki, H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin. Cancer Res. 15, 6002–6007 (2009). PMID: 19755387  

22. Nobusawa S, et al., (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007, PMID 19755387.

23. Lugowska, I. et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J. Cancer 9, 998–1005 (2018). PMID: 29581779  

23. Lugowska I, et al., (2018). IDH1/2 mutations predict shorter survival in chondrosarcoma. J Cancer 9:998–1005, PMID 29581779.

24. Amary, M. F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343 (2011). PMID: 21598255  

24. Amary MF, et al., (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334–343, PMID 21598255.

25. Pansuriya, T. C. et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat. Genet. 43, 1256–1261 (2011). PMID: 22057234  

25. Pansuriya TC, et al., (2011). Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43:1256–1261, PMID 22057234.

26. Wang, P. et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32, 3091–3100 (2013). PMID: 22824796

26. Wang P, et al., (2013). Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32:3091–3100, PMID 22824796.

27. Borger, D. R. et al. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. The Oncologist 17, 72–79 (2012). PMID: 22180306  

27. Borger DR, et al., (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist 17:72–79, PMID 22180306.

28. Churi, C. R. et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLOS ONE 9, e115383 (2014). PMID: 25536104  

28. Churi CR, et al., (2014). Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLOS ONE 9:e115383, PMID 25536104.

29. Goyal, L. et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. The Oncologist 20, 1019–1027 (2015). PMID: 26245674  

29. Goyal L, et al., (2015). Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. The Oncologist 20:1019–1027, PMID 26245674.

30. Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470–1473 (2013). PMID: 24185509  

30. Jiao Y, et al., (2013). Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45:1470–1473, PMID 24185509.

31. Mardis, E. R. et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. N. Engl. J. Med. 361, 1058–1066 (2009). PMID: 19657110  

31. Mardis, E. R. et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. N. Engl. J. Med. 361, 1058–1066 (2009). PMID: 19657110